Skip NavigationSkip to Content
Return Return to Search Results

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis

  1. Author:
    Brooks, A. D.
    Ramirez, T.
    Toh, U.
    Onksen, J.
    Elliott, P. J.
    Murphy, W. J.
    Sayers, T. J.

  2. Author Address

    NCI, SAIC Frederick Inc, Basic Res Program, Ft Detrick, MD 21702 USA. NCI, Expt Immunol Lab, Frederick, MD 21701 USA. Kurume Univ, Dept Surg, Kurume, Fukuoka 830, Japan. Combinatorex, Boston, MA USA. Univ Nevada, Reno, NV USA.;Sayers, TJ, NCI, SAIC Frederick Inc, Basic Res Program, Ft Detrick, MD 21702 USA.;sayers@mail.ncifcrf.gov
    1. Year: 2005
  2. Book Title: Tumor Progression and Therapeutic Resistance
  3. Series Title: Annals of the New York Academy of Sciences
  4. New York Acad Sciences
  5. New York
    1. 1059
    2. Pages: 160-167
  7. Type of Work: Book Chapter
  8. ISBN: 0077-8923
  1. Abstract:

    On testing a panel of different human cancer cell lines, we observed that the proteasome inhibitor bortezomib could dramatically sensitize some lines to the apoptotic effects of Apo2L/TRAIL. Certain renal, colon, or breast tumor cell lines were dramatically sensitized, whereas other tumor lines from the same tissue of origin remained resistant. This sensitization did not correlate with either the p53 status of the individual tumor cell lines or their intrinsic sensitivity to Apo2L/TRAIL. Colon cancer cell lines lacking p53 or Bax were sensitized by bortezomib, suggesting that neither p53 nor Bax levels were crucial for sensitization. Although the molecular basis of bortezomib sensitization of tumor cells to Apo2L/TRAIL remains to be determined, this combination can have an enhanced apoptotic effect over either agent alone for certain human cancer cells.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1196/annals.1339.042
  3. View record in Web of Science®
  4. WOS: 000236279200015

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel